Bristol-Myers v. Zenith
Executive Summary
Bristol-Myers files suit against Zenith charging infringement of its cephadroxil monohydrate patent. The drug is marketed by Bristol-Myers as Ultracef and by Mead Johnson as Duricef. Bristol-Myers maintains that the patent is active until March 12, 2002. Zenith obtained ANDA approval for cephadroxil on March 3. The generic firm says that it is not marketing the antibiotic product and does not plan to until patent issues are resolved.